Deployment of SAP® S/4HANA will help drive strategic growth
NEW YORK; Sept. 9, 2015 – Accenture (NYSE: ACN) has been selected by Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company, to support the transformation of its business operations and help enable strategic growth across the company’s healthcare lines of business.
Accenture will deploy the SAP® Business Suite 4 SAP HANA® (SAP S/4HANA) solution as the digital foundation for Horizon Pharma’s global enterprise resource planning system through the Accenture and SAP Business Solutions Group, and will also provide systems implementation, project management and change management services. The global deployment of SAP S/4HANA is intended to standardize and automate financial processes and reporting functions, and optimize production, logistics, sales, procurement and services for Horizon Pharma.
“We are pleased to team with Accenture to leverage SAP S/4HANA capabilities to provide global financial visibility as we reach new customers, drive growth and integrate acquired businesses,” said Paul W. Hoelscher, executive vice president, chief financial officer of Horizon Pharma.
“Horizon Pharma is one of the companies that experienced significant expansion as the industry spent more than $360 billion on mergers and acquisitions in 2014,” said Caspar Borggreve, managing director in Accenture’s Products operating group, Life Sciences. “In response, we are working with SAP to provide Horizon Pharma and other life sciences companies with rapid access to standardized financial capabilities as they integrate the acquired businesses.”
Accenture will deliver the work on site at Horizon Pharma, as well as from the Accenture Innovation Center for SAP in Kronberg, Germany and the Accenture Delivery Center in Bangalore, India. These centers are part of Accenture’s differentiated approach to delivering SAP-based solutions and services that help build the next generation of business solutions by combining advanced analytics, mobility, cloud and in-memory processing with core SAP technologies.
“We have a 40-year history of collaboration with Accenture, and remain committed to working together to help life sciences customers gather, standardize and normalize their data for greater visibility,” said Thack Brown, GM and global head of Line-of-Business Finance, SAP. “SAP S/4HANA is the next-generation business suite designed to help our customers simplify connections between people, business networks and devices in order to build more real-time business processes that deliver better value in the digital economy.”
Accenture is a global management consulting, technology services and outsourcing company, with more than 336,000 people serving clients in more than 120 countries. Combining unparalleled experience, comprehensive capabilities across all industries and business functions, and extensive research on the world’s most successful companies, Accenture collaborates with clients to help them become high-performance businesses and governments. The company generated net revenues of US$30.0 billion for the fiscal year ended Aug. 31, 2014. Its home page is www.accenture.com.
About Horizon Pharma plc
Horizon Pharma plc is a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets seven medicines through its orphan, primary care and specialty business units. Horizon’s global headquarters are in Dublin, Ireland. For more information, please visit www.horizonpharma.com.
SAP, SAP HANA and other SAP products and services mentioned herein as well as their respective logos are trademarks or registered trademarks of SAP SE (or an SAP affiliate company) in Germany and other countries. See http://www.sap.com/corporate-en/legal/copyright/index.epx for additional trademark information and notices.
All other product and service names mentioned are the trademarks of their respective companies.
SAP Forward-looking Statement
Any statements contained in this document that are not historical facts are forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to SAP are intended to identify such forward-looking statements. SAP undertakes no obligation to publicly update or revise any forward-looking statements. All forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from expectations The factors that could affect SAP’s future financial results are discussed more fully in SAP’s filings with the U.S. Securities and Exchange Commission ("SEC"), including SAP’s most recent Annual Report on Form 20-F filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates.
+ 1 312 693 5992